

# Two Predictors of Early Arthritis Identified

BY SHERRY BOSCHERT  
San Francisco Bureau

SAN FRANCISCO — An observational study of 395 patients with suspected early arthritis identified two factors that predicted a diagnosis of rheumatoid arthritis within a year's time.

Patients with swelling in a small joint of the hands and/or feet were six times more likely to be diagnosed with rheumatoid arthritis within a year than were patients whose swollen joints did not include those sites. A diagnosis of rheumatoid arthritis within a year was 39 times more likely in patients whose laboratory tests at baseline showed the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies, compared with anti-CCP-negative patients, Dr. Maria D. Mjaavatten reported at the annual meeting of the American College of Rheumatology.

The same factors also were predictive (though to a lesser degree) of persistent arthritis and of subsequent use of disease-modifying antirheumatic drugs within a year, added Dr. Mjaavatten of the department of rheumatology at Diakonhjemmet Hospital, Oslo.

Patients with small-joint arthritis were twice as likely to develop persistent arthritis and four times as likely to start a DMARD within a year compared with patients without small-joint involvement. Patients with anti-CCP positivity were five times more likely to develop persistent arthritis and nine times more likely to start a DMARD, compared with anti-CCP-negative patients.

The results will help inform an ongoing effort by a joint European-American task force to define new diagnostic criteria for early rheumatoid arthritis, Dr. Mjaavatten said. Classification criteria from the American College of Rheumatology (ACR) were developed in 1997 for established disease and are not as useful in early arthritis. The ACR and the European League Against Rheumatism (EULAR) convened the current task force.

"Rheumatoid arthritis is often undifferentiated. The disease course can be difficult to predict in the early stages," but the newly identified predictors should help, she said.

The study enrolled adult patients with at least a 16-week history of one or more clinically swollen joints diagnosed as arthritis by rheumatologists at one of five Norwegian centers, and followed patients for at least a year. Although physicians were aware of the ACR diagnostic criteria for rheumatoid arthritis, diagnoses were not limited to patients who met those criteria, Dr. Mjaavatten noted.

The cohort represented approximately 70% of all patients enrolled. The other 30% were lost to follow-up before completing at least two follow-up assessments and were presumed to have nonpersistent arthritis. The study defined persistent arthritis as the presence of joint swelling on at least two out of three follow-up assessments during the first year.

The cohort was younger (mean age, 46 years) and included fewer women (57%) than might be expected in a "typical" rheumatoid arthritis cohort, she noted. The mean arthritis duration at baseline was short (30 days), with a duration of 10 days or less in a quarter of the patients.

During the year of follow-up, 18% of patients were diagnosed with rheumatoid arthritis and 26% had persistent arthritis. Among 301 patients whose

charts had information on DMARDs, 36% started a DMARD during the year. Methotrexate was the dominant drug, used by 59% of patients on a DMARD. Another 9% used sulfasalazine, 28% took a combination of DMARDs or more than one DMARD during the year (including 13 patients who received biologics), and 4% used other DMARDs.

Some patients had more than one of the three main outcomes: a rheumatoid

arthritis diagnosis, persistent arthritis, or DMARD use. DMARDs were not started in approximately 5% of patients diagnosed with rheumatoid arthritis and about 15% of patients with persistent arthritis, Dr. Mjaavatten said. Around 16% of DMARD users had neither a diagnosis of rheumatoid arthritis nor persistent arthritis.

Dr. Mjaavatten reported no conflicts of interest regarding this study. ■



Because many depend on him  
you can depend  
on SKELAXIN®

## For acute, painful musculoskeletal conditions

SKELAXIN® (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

### Important Safety Information

Taking SKELAXIN® with food may enhance general CNS depression. Elderly patients may be especially susceptible to this CNS effect. The most frequent adverse reactions to metaxalone include nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, and nervousness or "irritability."

Please see adjacent page for full Prescribing Information.

Efficacy at work

**Skelaxin® 800mg**  
(metaxalone) Tablets



www.kingpharm.com www.skelaxin.com

SKELAXIN is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals®, Inc.  
Copyright © 2008 King Pharmaceuticals®, Inc. All rights reserved. SKES738

12/2008